Data from: A validated Tumor Control Probability model based on a meta-analysis of low, intermediate, and high-risk prostate cancer patients treated by photon, proton, or carbon-ion radiotherapy. 2015. doi:10.17195/candat.2015.10.8.
Data from: Development and Evaluation of an Online Three-Level Proton vs Photon Decision Support Prototype for Head and Neck Cancer - Comparison of Dose, Toxicity and Cost-Effectiveness. 2015. doi:10.17195/candat.2015.10.5.
Data from: MMP2 small immuno protein antibody uptake in xenograft tumors is associated with MMP2 activity. 2015. doi:10.17195/candat.2015.10.6.
Data from: Benefit of particle therapy in re-irradiation of head and neck patients. Results of a multicenter in silico ROCOCO trial. 2016. doi:10.17195/candat.2016.04.2.
Data from: Nitroglycerin in non-small cell lung cancer: does it impact tumor hypoxia and tumor perfusion? A window-of-opportunity clinical trial. 2016. doi:10.17195/candat.2016.07.2.
Data from: Prognostic value of blood-biomarkers related to hypoxia, inflammation, immune response and tumour load in non-small cell lung cancer – a survival model with external validation. 2016. doi:10.17195/candat.2016.04.1..
Data from: Quantitative assessment of Zirconium-89 labeled cetuximab using PETCT imaging in patients with advanced head and neck cancer - a theragnostic approach. 2016. doi:10.17195/candat.2016.11.1.
Data from: 4DCT imaging to assess radiomics feature stability: an investigation for thoracic cancers. 2017. doi:10.17195/candat.2017.05.1.
Data from: Developing and validating a survival prediction model for NSCLC patients through distributed learning across three countries. 2017. doi:10.17195/candat.2017.02.2.
Data from: Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images. 2017. doi:10.17195/candat.2017.02.1.